Oncolytics Biotech (NASDAQ:ONCY) Research Coverage Started at Raymond James

Research analysts at Raymond James assumed coverage on shares of Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) in a report released on Thursday, Benzinga reports. The firm set an "outperform" rating and a $3.00 price target on the stock. Raymond James' target price points to a potential upside of 160.87% from the company's current price.

A number of other equities analysts have also commented on ONCY. HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Oncolytics Biotech in a report on Wednesday, February 14th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Oncolytics Biotech in a report on Friday, January 12th.

Oncolytics Biotech Price Performance

ONCY traded up $0.05 during trading on Thursday, hitting $1.15. The company's stock had a trading volume of 850,680 shares, compared to its average volume of 396,939. The firm's 50 day moving average price is $1.07 and its 200-day moving average price is $1.39. The stock has a market cap of $86.73 million, a PE ratio of -3.87 and a beta of 1.93. Oncolytics Biotech has a twelve month low of $0.88 and a twelve month high of $3.39.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.07. Equities analysts anticipate that Oncolytics Biotech will post -0.32 earnings per share for the current year.

Institutional Investors Weigh In On Oncolytics Biotech

A number of institutional investors have recently modified their holdings of the stock. International Assets Investment Management LLC raised its stake in shares of Oncolytics Biotech by 33.9% in the 4th quarter. International Assets Investment Management LLC now owns 269,699 shares of the company's stock valued at $364,000 after purchasing an additional 68,246 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Oncolytics Biotech by 15.3% in the 1st quarter. Renaissance Technologies LLC now owns 129,856 shares of the company's stock valued at $156,000 after purchasing an additional 17,256 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Oncolytics Biotech in the 4th quarter valued at about $154,000. Advisor Resource Council acquired a new stake in shares of Oncolytics Biotech in the 4th quarter valued at about $135,000. Finally, BNP Paribas Arbitrage SNC raised its stake in shares of Oncolytics Biotech by 778.6% in the 2nd quarter. BNP Paribas Arbitrage SNC now owns 68,320 shares of the company's stock valued at $178,000 after purchasing an additional 60,544 shares in the last quarter. Institutional investors and hedge funds own 6.82% of the company's stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.